Cancer Immunotherapy Companies

Cancer Immunotherapy Companies: Review

As cancer immunothrerapy has become more and more popular in research, a lot of companies have focused on this area to seek for ways for cancer treatments. 10 most famous cancer immunotherapy companies are listed here:

Incyte Corporation

Incyte put their efforts on immune checkpoint inhibitors. The most famous are IDO inhibitors, PD-1 inhibitors under clinical trials.

Juno Therapeutics

The use of human T cells as therapeutics to re-engage the immune system has the potential to revolutionize the way cancer is treated. Juno's technologies genetically engineer a patient's own T cells to recognize and kill cancer cells. These cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. Two different technologies are used to target cancer cells and activate T cells, CARs and TCRs.

Bluebird bio

Cancer immunotherapy research group in bluebird is based on CAR T cells presents a promising new treatment option. They focused on the next generation of T cell engineering and creating a pipeline of T cell product candidates to treat a wide variety of liquid and solid tumor cancers. based on CAR T cells presents a promising new treatment option.

Celldex Therapeutics

Celldex's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines.

Tesaro, Inc.

In Tesaro, Inc., by blocking the interaction of PD-1, TIM-3 and LAG-3 with their respective ligands, antibodies to these targets aim to restore immune anti-cancer function in patients across a variety of tumor types.

Kite Pharma

They are developing engineered autologous T cells that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Their dual platform has the potential to address both hematological and solid tumor cancers.

NewLink Genetics

Their immuno-oncology pipeline includes HyperAcute® Cellular Immunotherapies and small molecule product candidates, such as cellular immunotherapy IDO inhibitor, and designed to harness multiple components of the immune system to combat a wide range of cancers without significant incremental toxicity, either as monotherapy or in combination with other treatment regimens.


ZIOPHARM Oncology and its partner Intrexon Corporation, a leader in synthetic biology, together with collaborators at The University of Texas MD Anderson Cancer Center, are employing novel cell engineering techniques and multigenic gene programs to develop next-generation patient- and donor-derived adoptive cellular therapies based on designer cytokines, such as genetically modified T cells and NK cells, to target hematologic malignancies and solid tumors as well as graft-versus-host-disease. These technologies are designed to improve safety and decrease the cost, time and complexity of development associated with cell-based therapies.

Atara Biotherapeutics

T-cell product candidates include Epstein-Barr virus (EBV)-targeted cytotoxic T lymphocytes (CTLs), cytomegalovirus (CMV)-targeted CTLs, and Wilms Tumor 1 (WT1)-targeted CTLs. These T-cell product candidates are designed to target cancer cells or cells infected with certain viruses and kill them. Each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have few therapeutic options today.


Cellectis is a pioneering gene editing company, employing core proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology. Our product candidates, based on gene-edited T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers.
More and more companies have participated in the range of cancer immuotherapy research, which will offer new hope for cancer therapeutic research.